US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emmis Acquisition Corp

10.06

0.0000

Volume:1.56K

Turnover:15.73K

Market Cap:158.70M

PE:-1.48K

High:10.06

Open:10.06

Low:10.06

Close:10.06

52wk High:10.09

52wk Low:9.90

Shares:15.78M

Float Shares:11.50M

Volume Ratio:0.47

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0068

EPS(LYR):-0.1655

ROE:--

ROA:--

PB:--

PE(LYR):-60.80

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Emmis Acquisition Corp

Exchange:

NASDAQ

Establishment Date:

2025

Employees:

- -

Office Location:

515 E Las Olas Boulevard,Suite 120,Fort Lauderdale,Florida,United States

Website:

http://www.emisphere.com

Zip Code:

33301

Phone:

Fax:

- -

Introduction:

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Directors

Name

Position

Peter Goldstein

Chairman of the Board and Chief Executive Officer

David Lowenstein

Chief Financial Officer and Director

Anna C Mallon

Director

Low Koon Poh

Director

Seth Farbman

Director

Shareholders

Name

Position

Peter Goldstein

Chairman of the Board and Chief Executive Officer

David Lowenstein

Chief Financial Officer and Director

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EMIS/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMIS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMIS\",,,,,undefined,":{"symbol":"EMIS","market":"US","secType":"STK","nameCN":"Emmis Acquisition Corp","latestPrice":10.06,"timestamp":1770843600000,"preClose":10.06,"halted":0,"volume":1564,"delay":0,"changeRate":0,"floatShares":11500000,"shares":15775800,"eps":-0.0068,"marketStatus":"Closed","change":0,"latestTime":"02-11 16:00:00 EST","open":10.06,"high":10.06,"low":10.06,"amount":15731.92,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0068,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":10.06,"volumeRatio":0.466894},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMIS\",,,,,undefined,":{"symbol":"EMIS","floatShares":11500000,"roa":"--","roe":"--","lyrEps":-0.165454,"volumeRatio":0.466894,"shares":15775800,"dividePrice":0,"high":10.06,"amplitude":0,"preClose":10.06,"low":10.06,"week52Low":9.9,"pbRate":"--","week52High":10.09,"institutionHeld":0,"latestPrice":10.06,"eps":-0.0068,"divideRate":0,"volume":1564,"delay":0,"ttmEps":-0.0068,"open":10.06,"prevYearClose":9.95,"prevWeekClose":10.06,"prevMonthClose":10.06,"prevQuarterClose":9.95,"fiveDayClose":10.06,"twentyDayClose":9.96,"sixtyDayClose":9.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMIS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMIS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMIS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1951829973,"yearFounded":2025,"address":"515 E Las Olas Boulevard,Suite 120,Fort Lauderdale,Florida,United States","zipCode":"33301","officePhone":"(954) 294-6285"},"stockCompanyDetail":{"websiteUrl":"http://www.emisphere.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0151},{"period":"ytd","weight":0.0111}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.","exchange":"NASDAQ","name":"Emmis Acquisition Corp","nameEN":"Emmis Acquisition Corp"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"EMIS\",market:\"US\",,,undefined,":{"directors":[{"name":"Peter Goldstein","position":"Chairman of the Board and Chief Executive Officer"},{"name":"David Lowenstein","position":"Chief Financial Officer and Director"},{"name":"Anna C Mallon","position":"Director"},{"name":"Low Koon Poh","position":"Director"},{"name":"Seth Farbman","position":"Director"}],"executives":[{"name":"Peter Goldstein","position":"Chairman of the Board and Chief Executive Officer"},{"name":"David Lowenstein","position":"Chief Financial Officer and Director"}]}}}